WallStreetZen

NASDAQ: CYTK
Cytokinetics Inc Stock Forecast, Predictions & Price Target

Analyst price target for CYTK

Based on 6 analysts offering 12 month price targets for Cytokinetics Inc.
Min Forecast
$40.00+8.37%
Avg Forecast
$54.00+46.3%
Max Forecast
$75.00+103.2%

Should I buy or sell CYTK stock?

Based on 6 analysts offering ratings for Cytokinetics Inc.
Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

CYTK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Mizuho
Top 37%
64
Strong BuyMaintains$54.00+46.30%2021-12-01
HC Wainwright & Co.
Top 12%
89
BuyMaintains$62.00+67.98%2021-11-04
Morgan Stanley
Top 37%
64
Strong BuyMaintains$45.00+21.92%2021-10-08
Jefferies
Top 42%
59
Strong BuyInitiates Coverage On$75.00+103.20%2021-10-07
Barclays
Bottom 14%
14
Strong BuyMaintains$40.00+8.37%2021-07-20
Needham
Bottom 3%
3
BuyMaintains$48.00+30.05%2021-07-19
Anonymous
Morgan Stanley
Strong BuyMaintains$35.00-5.17%2021-04-19

1 of 1

Forecast return on equity

Is CYTK forecast to generate an efficient return?
Company
-117.9%
Industry
21.88%
Market
37.5%
CYTK's Return on Equity is forecast to be low in 3 years (-117.9%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is CYTK forecast to generate an efficient return on assets?
Company
-35.48%
Industry
6.66%
CYTK is forecast to generate lower Return on Assets (-35.48%) than the US Biotechnology industry average (6.66%)
Forecast

CYTK earnings per share forecast

What is CYTK's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$3.02-2.58%
Avg 2 year Forecast
-$3.17+2.26%
Avg 3 year Forecast
-$2.88-7.1%

CYTK revenue forecast

What is CYTK's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$21.1M-2.09%
Avg 2 year Forecast
$40.0M+85.64%
Avg 3 year Forecast
$71.8M+233.04%
CYTK's revenue is forecast to grow at an exceptional rate of 47.37% per year
Forecast

CYTK revenue growth forecast

How is CYTK forecast to perform vs Biotechnology companies and vs the US market?
Company
47.37%
Industry
30.03%
Market
10.08%
CYTK's revenues are forecast to grow faster (47.37% per year) than the US Biotechnology industry average (30.03%)
Forecast
CYTK's revenues are forecast to grow faster (47.37% per year) than the US market average (10.08%)
Forecast

Cytokinetics Stock Forecast FAQ

Is Cytokinetics Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: CYTK) stock is to Strong Buy CYTK stock.

Out of 6 analysts, 4 (66.67%) are recommending CYTK as a Strong Buy, 2 (33.33%) are recommending CYTK as a Buy, 0 (0%) are recommending CYTK as a Hold, 0 (0%) are recommending CYTK as a Sell, and 0 (0%) are recommending CYTK as a Strong Sell.

What is CYTK's earnings growth forecast for 2021-2023?

(NASDAQ: CYTK) Cytokinetics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 6.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.37%.

Cytokinetics's earnings in 2021 is -$228,674,000.On average, 5 Wall Street analysts forecast CYTK's earnings for 2021 to be $-253,326,518, with the lowest CYTK earnings forecast at $-266,747,791, and the highest CYTK earnings forecast at $-241,582,905. On average, 5 Wall Street analysts forecast CYTK's earnings for 2022 to be $-265,908,961, with the lowest CYTK earnings forecast at $-301,978,631, and the highest CYTK earnings forecast at $-195,447,280.

In 2023, CYTK is forecast to generate $-241,582,905 in earnings, with the lowest earnings forecast at $-291,912,676 and the highest earnings forecast at $-191,253,133.

What is CYTK's revenue growth forecast for 2021-2023?

(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 47.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.03%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Cytokinetics's revenue in 2021 is $21,550,000.On average, 5 Wall Street analysts forecast CYTK's revenue for 2021 to be $1,769,930,308, with the lowest CYTK revenue forecast at $1,280,892,692, and the highest CYTK revenue forecast at $1,962,861,100. On average, 4 Wall Street analysts forecast CYTK's revenue for 2022 to be $3,355,737,535, with the lowest CYTK revenue forecast at $1,761,542,013, and the highest CYTK revenue forecast at $7,047,845,711.

In 2023, CYTK is forecast to generate $6,020,279,537 in revenue, with the lowest revenue forecast at $2,348,722,684 and the highest revenue forecast at $10,417,423,933.

What is CYTK's forecast return on assets (ROA) for 2021-2024?

(NASDAQ: CYTK) forecast ROA is -35.48%, which is lower than the forecast US Biotechnology industry average of 6.66%.

What is CYTK's Price Target?

According to 6 Wall Street analysts that have issued a 1 year CYTK price target, the average CYTK price target is $54.00, with the highest CYTK stock price forecast at $75.00 and the lowest CYTK stock price forecast at $40.00.

On average, Wall Street analysts predict that Cytokinetics's share price could stay at $54.00 by Dec 1, 2022. The average Cytokinetics stock price prediction forecasts a potential downside of N/A from the current CYTK share price of $36.91.

What is CYTK's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: CYTK) Cytokinetics's current Earnings Per Share (EPS) is -$3.10. On average, analysts forecast that CYTK's EPS will be $-3.02 for 2021, with the lowest EPS forecast at $-3.18, and the highest EPS forecast at $-2.88. On average, analysts forecast that CYTK's EPS will be $-3.17 for 2022, with the lowest EPS forecast at $-3.60, and the highest EPS forecast at $-2.33. In 2023, CYTK's EPS is forecast to hit $-2.88 (min: $-3.48, max: $-2.28).

What is CYTK's forecast return on equity (ROE) for 2021-2024?

(NASDAQ: CYTK) forecast ROE is -117.9%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.